Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from KALA BIO ( (KALA) ).
On January 8, 2026, KALA BIO, Inc. entered into an at-the-market equity offering agreement with H.C. Wainwright & Co., allowing the company to issue and sell up to $15 million of its common stock from time to time through Wainwright as sales agent or, in certain cases, principal. Under the arrangement, KALA BIO retains full discretion over sales parameters, pays a 3% commission on gross proceeds and certain expense reimbursements to Wainwright, and may suspend or opt not to sell shares at any time, meaning the program primarily creates financing flexibility and potential access to incremental capital rather than immediately altering the company’s capital structure.
The most recent analyst rating on (KALA) stock is a Hold with a $0.60 price target. To see the full list of analyst forecasts on KALA BIO stock, see the KALA Stock Forecast page.
Spark’s Take on KALA Stock
According to Spark, TipRanks’ AI Analyst, KALA is a Neutral.
The score is primarily weighed down by weak financial performance (minimal revenue, large losses, heavy cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Corporate events are mixed—debt overhang reduction helps, but Nasdaq compliance and prior distressed developments keep risk elevated; valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on KALA stock, click here.
More about KALA BIO
Average Trading Volume: 7,890,627
Technical Sentiment Signal: Sell
Current Market Cap: $15.31M
For a thorough assessment of KALA stock, go to TipRanks’ Stock Analysis page.